ETF Daily News1 个月
The Goldman Sachs Group Cuts Lineage (NASDAQ:LINE) Price Target to $77.00
Lineage (NASDAQ:LINE – Free Report) had its price objective trimmed by The Goldman Sachs Group from $89.00 to $77.00 in a research report sent to investors on Friday,Benzinga reports.
Lineage Cell Therapeutics’ (LCTX) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a report released on Tuesday morning,Benzinga reports. The firm currently has a ...